BiologicalDrug
CV-8102 clinical trials
Also written CV8102.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Therapeutic Liver Cancer Peptide Vaccine IMA970A (1) · Cyclophosphamide (1) · Rabies virus strain flury LEP antigen (propiolactone inactivated) (1)
Studies
Open first, then newest update. How each study uses CV-8102 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACCStatus unknownPhase 1CureVacNCT03291002Written as CV8102
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma PatientsCompletedPhase 1/2National Cancer Institute, NaplesNCT03203005Written as IMA970A plus CV8102 and Cyclophosphamide
- Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy AdultsCompletedPhase 1CureVacNCT02238756Written as CV8102
Codes
What other systems call CV-8102 · ClinicalTrials.gg INT018139
- UNII (FDA) ULM5THL8W5CV-8102One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ULM5THL8W5 | CV-8102 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.